HLS Therapeutics Inc
TSX:HLS

Watchlist Manager
HLS Therapeutics Inc Logo
HLS Therapeutics Inc
TSX:HLS
Watchlist
Price: 4.91 CAD 0.82% Market Closed
Market Cap: 153.6m CAD

HLS Therapeutics Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

HLS Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
HLS Therapeutics Inc
TSX:HLS
Cash from Operating Activities
$13.8m
CAGR 3-Years
-7%
CAGR 5-Years
19%
CAGR 10-Years
9%
No Stocks Found

HLS Therapeutics Inc
Glance View

Market Cap
153.6m CAD
Industry
Health Care

HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

HLS Intrinsic Value
11.77 CAD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is HLS Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
13.8m USD

Based on the financial report for Sep 30, 2025, HLS Therapeutics Inc's Cash from Operating Activities amounts to 13.8m USD.

What is HLS Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
9%

Over the last year, the Cash from Operating Activities growth was 62%. The average annual Cash from Operating Activities growth rates for HLS Therapeutics Inc have been -7% over the past three years , 19% over the past five years , and 9% over the past ten years .

Back to Top